Side-by-side comparison of AI visibility scores, market position, and capabilities
Copenhagen YC W21 lab automation robots for biotech at $28.2M total ($20M Astanor Series A Apr 2024) and $8.3M revenue 2024; 500K+ hours saved annually serving alternative protein and sustainable ag competing with Opentrons for microbiology automation.
Reshape Biotech is a Copenhagen, Denmark-based laboratory automation robotics company — backed by Y Combinator (W21) with $28.2 million in total funding including a $20 million Series A led by Astanor Ventures in April 2024 with participation from YC — providing biotechnology companies, life sciences research organizations, and food technology companies with specialized single-function robots that automate repetitive microbiological laboratory workflows, generating $8.3 million in annual revenue in 2024 with a 55-person team. Reshape's robots have saved customers over 500,000 hours of manual lab work annually, serving the sustainable food technology and alternative protein sector (fermentation-based food production, precision fermentation, cultivated meat) alongside traditional biotech research laboratories that use microbiology workflows at scale.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.